Impact of Inflation on the Healthcare Sector by Physicians Perspective, Patient Treatment, Regional Analysis, Drug Prices and Treatment Costs - Thematic Intelligence
Impact of Inflation on the Healthcare Sector by Physicians Perspective, Patient Treatment, Regional Analysis, Drug Prices and Treatment Costs - Thematic Intelligence
Summary
In this Inflation in the Healthcare Sector - Physician Perspective report-tracker, GlobalData continues to examine the impact of inflation on healthcare systems, patients, and HCPs. The report provides an overview of the current and future outlook of the healthcare sector, government policies, innovative technologies, and initiatives that are expected to help combat inflation in the healthcare sector.
Key takeaways from this report include -
The healthcare industry continues to face the challenges such as persistent inflation in a post-COVID-19 world.
Even though inflation is on its way down, it will remain elevated in 2023, continuing to pressure the healthcare sector.
Although situation has improved in most of the countries, risings costs still triggered patients to postpone or stop treatments in H1 2023.
Despite some improvement, “out of pocket” costs were an important factor for patients when choosing a treatment in H1 2023.
Surveyed HCPs expected drug prices to grow with inflation rate.
Despite the pharma industry’s skepticism, US HCPs believed that the Inflation Reduction Act could lead to lower drug prices.
Physicians agreed that biosimilars could provide costs savings for the patients and healthcare systems and their use should be encouraged.
Drug pricing control and movement towards preventive care were highlighted as the top solutions to reduce inflation in the healthcare sector.
Key Highlights
Despite decreasing inflation rates, the healthcare sector will face turbulent times in 2023. Despite some improvement, rising costs are forcing patients to postpone or stop treatments; it will take years for the backlogs to clear. Drug pricing control and movement towards preventive care may be reliable methods to reduce inflation in the healthcare sector.
Scope
This report combines information obtained from secondary sources and primary research with healthcare industry professionals, key opinion leaders (KOLs), and physicians from different therapy areas (medical oncology, hematology, cardiology, vascular medicine, primary care, internal medicine, endocrinology, gynecology/obstetrics, orthopedic surgery, and gastroenterology). The interviews and surveys with physicians and KOLs were conducted between January 2023-May 2023.
Study objectives
Assess the impact of inflation on the healthcare sector
Highlight the impact of inflation on patient treatment
Capture physicians’ opinions on drug price growth
Identify possible inflation reduction measures in the healthcare sector
Explore physicians’ views on inflation reduction acts, such as the IRA
Assess physicians’ opinions on biosimilar use as a mean to provide cost savings
Compare results with previous, 2022 survey findings
Reasons to Buy
Develop and design your corporate strategies post-Brexit through an in-house expert analysis of the key factors to impact the post-Brexit UK healthcare industry.
Develop business strategies by understanding the key factors to impact healthcare research and manufacturing in the UK post-Brexit.
Stay up to date on the industry’s changing sentiment towards Brexit from within the healthcare industry.
Identify emerging industry trends post-Brexit to gain a competitive advantage.
Understand current macro events impacting healthcare industry in the UK post-Brexit.
1 Executive Summary
1.1 Executive Summary
2 Study Design
2.1 Objectives and Design
2.2 Respondent Mix
2.3 Respondent Profiles
3 Economic Outlook
3.1 Emerging Regulatory and Macroeconomic Trends
3.2 Inflation’s Impact on Pharmaceutical Value Chain
3.3 Industry’s Growth for the Next 12 Months
3.4 Economic Outlook - Major Markets Data
3.5 Health Spending
3.6 Retail Pharmaceutical Spending
4 Inflation in the US, 5EU, China and Japan
4.1 Inflation - US
4.2 Inflation Reduction Policies - US
4.3 Inflation - France
4.4 Inflation - Germany
4.5 Inflation Reduction Policies in the EU - France and Germany
4.6 Inflation - Italy
4.7 Inflation - Spain
4.8 Inflation Reduction Policies in the EU - Italy and Spain
4.9 Gas and Electricity Prices for Household Consumers: France, Germany, Italy, and Spain
4.10 Inflation - UK
4.11 Inflation - Japan
4.12 Inflation - China
4.13 Inflation Reduction Policies - UK, China, and Japan
5 Inflation - Impact on Patient Treatment
5.1 Inflation - Impact on Patient Treatment: US
5.2 Pharma’s Annual Drug Price Increases - US
5.3 Inflation - Impact on Patient Treatment: Italy
5.4 Inflation - Impact on Patient Treatment: France
5.5 Inflation - Impact on Patient Treatment: UK
5.6 Inflation - Impact on Patient Treatment: Germany
5.7 Inflation - Impact on Patient Treatment: Spain
5.8 Inflation - Impact on Patient Treatment: Japan
5.9 Inflation - Impact on Patient Treatment: China
5.10 Inflation - Impact on Patient Treatment: 2022 vs. 2023 H1 Data
6 Inflation - Drug Prices and Treatment Costs
6.1 Inflation - Treatment Costs: US
6.2 Inflation Reduction Act - a Closer Look
6.3 Inflation Reduction Act - HCP Perspective
6.4 Inflation - Treatment Costs: France
6.5 Inflation - Treatment Costs: Germany
6.6 Inflation - Treatment Costs: Italy
6.7 Inflation - Treatment Costs: Spain
6.8 Inflation - Treatment Costs: UK
6.9 NHS England Backlog Data - Consultant-led Elective Care
6.10 Inflation - Treatment Costs: Japan
6.11 Inflation - Treatment Costs: China
6.12 Inflation - Treatment Costs: 2022 vs. H1 2023 Data